MDxHealth SA
MDXHHealthcareNASDAQDiagnostics & Research · Last scanned Jul 22, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of May 20
Headquartered within the healthcare sector, MDxHealth SA focuses on Diagnostics & Research services and products. MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company carries a $45.2M market cap, placing it firmly in the micro-cap category. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.
Market Cap
$45.2M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-6.77
EPS (TTM)
$-0.67
EPS (Fwd)
$-0.13
ROE
—
ROA
-6.4%
Cash
$43.2M
Total Debt
$105.9M
Free CF
-$15.7M
52W Change
-57.3%
Annual Financials
Cash vs Debt
Where MDXH stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, MDXH finished 72.67% below its 150-day moving average ($3.22) and 73.65% below its 200-day moving average ($3.34). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MDXH overbought or oversold?
At the July 15, 2026 close, MDXH's RSI(14) was 10.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, MDXH has $43.2M in cash with $105.9M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$15.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has grown from $37.1M (2022) to $107.9M (2025), reflecting a 191% increase over the period.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence MDxHealth SA's trajectory.